Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 376 to 390 of 1251 results for public health guidance

  1. Dabrafenib, trametinib or both for treating BRAF V600 mutation-positive unresectable or metastatic melanoma in people aged 12 and over [TSID11838]

    Awaiting development Reference number: GID-TA11275 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Ovarian, fallopian tube, peritoneal cancer (platinum sensitive) - rucaparib (with nivolumab, maintenance, after 1 therapy) [ID6128]

    Awaiting development Reference number: GID-TA11216 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Dostarlimab for treating primary advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency when systemic treatment is suitable [ID6660]

    Awaiting development Reference number: GID-TA11870 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Gemcitabine intravesical delivery system for treating high-risk non-muscle-invasive bladder cancer untreated with BCG [ID6658]

    Awaiting development Reference number: GID-TA11868 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Sacituzumab govitecan for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment [ID6592]

    Awaiting development Reference number: GID-TA11769 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. LAM-561 with radiotherapy and temozolomide for treating IDH1 wild-type glioblastoma [ID4022]

    Awaiting development Reference number: GID-TA11741 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Sonesitatug vedotin for previously treated metastatic claudin 18.2-positive gastric or gastro-oesophageal junction adenocarcinomar [ID6669]

    Awaiting development Reference number: GID-TA11879 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Niraparib with abiraterone acetate and prednisone for treating hormone-sensitive metastatic prostate cancer [ID6595]

    Awaiting development Reference number: GID-TA11558 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Somapacitan for treating growth failure associated with being small for gestational age, Noonan syndrome or idiopathic short height [ID6536]

    Awaiting development Reference number: GID-TA11641 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Ranibizumab port delivery system for treating diabetic macular oedema [ID6137]

    Awaiting development Reference number: GID-TA11065 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Gemcitabine intravesical delivery system for treating recurrent high-risk papillary non-muscle-invasive bladder after BCG [ID6657]

    Awaiting development Reference number: GID-TA11872 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Durvalumab for adjuvant treatment of hepatocellular carcinoma at high risk of recurrence after curative liver resection or ablation [ID6206]

    Awaiting development Reference number: GID-TA11161 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Zongertinib for treating HER2-mutated unresectable or metastatic non-small-cell lung cancer [ID6573]

    Awaiting development Reference number: GID-TA11755 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Tirzepatide for treating type 2 diabetes in people 10 to 17 years [ID6539]

    Awaiting development Reference number: GID-TA11700 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Concizumab for treating severe haemophilia A or moderate to severe haemophilia B in people 12 years and over without inhibitors [ID5099]

    Awaiting development Reference number: GID-TA10972 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development